Approved in FL: ~90-minute infusion1,* click to learn more
A Commitment to Innovation.
A Continuum of Approvals Across FL & CLL
It’s Time to Rethink GAZYVA® (obinutuzumab)
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.